Generic Semaglutide Could Cut Canadian Drug Costs by 65%
Generic semaglutide medications could reduce Canadian drug plan costs by 65% once Health Canada approves competing versions of the active ingredient found in Ozempic and Wegovy.
Industry Projects Major Savings
According to Benefits and Pensions Monitor analysis, the patent expiration that occurred in January 2026 is expected to trigger substantial price competition in Canada's semaglutide market. The 65% cost reduction projection comes as employer benefit plans prepare for what could be the largest shift in GLP-1 medication pricing since these drugs entered the Canadian market.
Health Canada is currently reviewing nine generic semaglutide applications through its generic semaglutide tracker, with submissions from major manufacturers including Sandoz, Apotex, Teva, and other companies seeking to compete with Novo Nordisk's branded products.
Timeline and Market Impact
The benefits industry analysis suggests that while generic approvals may slip into late 2026, the eventual price reductions will significantly impact drug plan budgets across Canada. Current brand-name semaglutide products retail for approximately CAD $300-400 monthly, meaning a 65% reduction could bring costs down to around CAD $105-140 monthly.
Health Canada's standard 180-day review timeline for generic applications means the first approvals could arrive as early as mid-2026, though complex submissions may require additional review time.
Employer Plan Preparations
Canadian employer drug plans are already adjusting their formularies and coverage policies in anticipation of generic competition. The projected savings represent one of the most significant cost reductions expected in the prescription drug market, particularly given the high utilization of GLP-1 medications across employer plans.
Benefits consultants are advising plan sponsors to prepare for both the initial cost savings and potential increased utilization that typically accompanies generic drug launches.
Regulatory Status
The nine generic applications under Health Canada review include submissions for various strengths and formulations of semaglutide. Companies have been preparing manufacturing capabilities and regulatory submissions since the January patent expiration opened the Canadian market to competition.
Plan administrators can monitor approval progress through Health Canada's public submissions tracker and utilize insurance coverage checker tools to understand current and future coverage options.
Market Competition Expected
The 65% price reduction projection reflects expectations for robust competition among multiple generic manufacturers. Historical generic drug launches in Canada have typically seen price reductions of 25-50%, making the projected 65% reduction particularly significant for the semaglutide market.
Generic manufacturers are expected to compete aggressively on pricing given the large market opportunity and high current costs of branded semaglutide products in Canada.
Additional information about GLP-1 medication approvals and pricing is available in our FAQ section.
This article is for informational purposes only and does not constitute medical advice.
Get notified when generic prices go live
We’ll send one email the moment generic semaglutide prices are listed at Canadian pharmacies. No spam.
Get notified when generic semaglutide becomes available in Canada
Expected Q3 2026 — be the first to know
